Ireland Construction Growth Slows In April

Ireland's construction sector growth eased for the second straight month in April, marking the weakest rise in the current one-year sequence of growth as demand dropped for the first time in over a year, survey data from S&P Global showed on Monday.

The BNP Paribas Real Estate Irealand Construction Purchasing Managers' Index fell to 52.5 in April from 53.9 in March. Any reading above 50 indicates growth in the sector.

Housing activity and commercial projects increased at a softer pace in April, while civil engineering declined for the second month in a row.

New orders fell for the first time in over a year in April.

Input prices rose at the second-fastest rate since the survey began in June 2000.

Companies continued to increase their employment level and purchasing activity, while the rate of job creation rose slightly and purchasing activity grew at a slower pace.

Suppliers' delivery time lengthened in April with the war in Ukraine disrupting supply chains.

Sentiment improved from March's seventeen-month low, but was the second-lowest in the past year-and-a-half and below the series average.

"This is no surprise as the pipeline of office and logistics property to be delivered this year is at its highest since 2008," John McCartney, director & head of research at BNP Paribas Real Estate Ireland, said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT